Arrivent BioPharma, Inc. (AVBP)
16.48
+0.02
(+0.12%)
USD |
NASDAQ |
Oct 13, 10:38
Arrivent BioPharma Enterprise Value : 422.57M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 422.57M |
| October 09, 2026 | 435.62M |
| October 08, 2026 | 434.65M |
| October 07, 2026 | 443.35M |
| October 06, 2026 | 356.37M |
| October 05, 2026 | 1.002B |
| October 02, 2026 | 993.23M |
| October 01, 2026 | 1.025B |
| September 30, 2026 | 1.090B |
| September 29, 2026 | 1.055B |
| September 28, 2026 | 1.043B |
| September 25, 2026 | 1.002B |
| September 24, 2026 | 1.082B |
| September 23, 2026 | 1.091B |
| September 22, 2026 | 1.092B |
| September 21, 2026 | 1.064B |
| September 18, 2026 | 1.024B |
| September 17, 2026 | 997.58M |
| September 16, 2026 | 963.27M |
| September 15, 2026 | 978.73M |
| September 14, 2026 | 1.008B |
| September 11, 2026 | 1.029B |
| September 10, 2026 | 1.014B |
| September 09, 2026 | 1.067B |
| September 08, 2026 | 1.090B |
| Date | Value |
|---|---|
| September 04, 2026 | 1.123B |
| September 03, 2026 | 1.127B |
| September 02, 2026 | 1.101B |
| September 01, 2026 | 1.084B |
| August 31, 2026 | 1.079B |
| August 28, 2026 | 1.085B |
| August 27, 2026 | 1.125B |
| August 26, 2026 | 1.132B |
| August 25, 2026 | 1.142B |
| August 24, 2026 | 992.74M |
| August 21, 2026 | 1.034B |
| August 20, 2026 | 1.037B |
| August 19, 2026 | 1.078B |
| August 18, 2026 | 1.077B |
| August 17, 2026 | 1.029B |
| August 14, 2026 | 1.053B |
| August 13, 2026 | 1.077B |
| August 12, 2026 | 1.147B |
| August 11, 2026 | 1.144B |
| August 10, 2026 | 1.125B |
| August 07, 2026 | 1.117B |
| August 06, 2026 | 1.126B |
| August 05, 2026 | 1.106B |
| August 04, 2026 | 1.149B |
| August 03, 2026 | 1.059B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.458B |
| Alnylam Pharmaceuticals, Inc. | 30.04B |
| Anika Therapeutics, Inc. | 260.79M |
| Savara, Inc. | 851.51M |
| Vericel Corp. | 2.011B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.89M |
| Total Expenses (Quarterly) | 49.89M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -22.34% |
| Normalized Earnings Yield | -22.34 |